prikaz prve stranice dokumenta Liječenje vaskulitisa
  Download
PDF 489.24 KB
Professional paper - Professional paper
Liječenje vaskulitisa
Reumatizam, 60 (2013), 2; 47-54. urn:nbn:hr:184:313295
Novak, Srđan

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Novak, S. (2013). Liječenje vaskulitisa. Reumatizam, 60. (2), 47-54. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:313295

Novak, Srđan. "Liječenje vaskulitisa." Reumatizam, vol. 60, no. 2, 2013, pp. 47-54. https://urn.nsk.hr/urn:nbn:hr:184:313295

Novak, Srđan. "Liječenje vaskulitisa." Reumatizam 60, no. 2 (2013): 47-54. https://urn.nsk.hr/urn:nbn:hr:184:313295

Novak, S. (2013) 'Liječenje vaskulitisa', Reumatizam, 60(2), pp. 47-54. Available at: https://urn.nsk.hr/urn:nbn:hr:184:313295 (Accessed 12 May 2024)

Novak S. Liječenje vaskulitisa. Reumatizam [Internet]. 2013 [cited 2024 May 12];60(2):47-54. Available at: https://urn.nsk.hr/urn:nbn:hr:184:313295

S. Novak, "Liječenje vaskulitisa", Reumatizam, vol. 60, no. 2, pp. 47-54, 2013. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:313295. [Accessed: 12 May 2024]

Metadata
Title (croatian)Liječenje vaskulitisa
Title (english)Treatment of vasculitis
AuthorSrđan Novak
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (croatian)
Liječenje vakulitisa ovisi o etiologiji i tipu vaskulitisa. U liječenju sistemskih vaskulitisa glukokortikodi su prvi lijekovi izbora. Dok je u vaskulitisima velikih krvnih žila često dovoljna primjena samo glukokortikoida u s ANCA povezanim vaskulitisima gotovo uvijek je potrebna inicijalna kombinacija glukokortikoida i imunosupresiva (u težim oblicima ciklofosfamid, a u lakšim metotreksat ili azatioprin). Terapija održavanja u s ANCA povezanim vaskulitisima obično je meotreksat ili azatioprin. Od bioloških lijekova dosta se očekuje od primjene tocilizumaba u giganatocelularnom arteritisu, dok je u s ANCA povezanim vaskulitisma nedavno od regualatornih tijela odobrena primjena rituksimaba koji se smatra jednakovrijedan ciklofosfamidu u indukciji remisije, a preferira se u relapsnim oblicima bolesti.
Abstract (english)
Treatment of vasculitis depends on etiology and type of vasculitis. Gluccocorticoids are drug of choice in treatment of systemic vasculitis. While in vasculitis of large vessels treatment with gluccocorticoids is often sufficient, in ANCA associated vasculitis almost always intial combination of gluccocorticoids and immunosupresive drugs (cyclofosfamide in severe forms; azatioprin and metotrrexate in moderate disease) is needed. Maintance therapy of ANCA associated vasculitis is methotrexate or azatioprin. From biologic therapy, in gigantocellular vasculitis treatment with tocilizumb has a great expectation, while in ANCA associated vasculitis recently rituximab was approved by regulatory agencies, and it is nontinferior to cyclofosfamide in induction of remission and prefarable in relapsing disease.
Keywords (croatian)
Keywords (english)
Languagecroatian
Languageenglish
Publication typeProfessional paper - Professional paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleReumatizam
Numberingvol. 60, no. 2, pp. 47-54
p-ISSN0374-1338
e-ISSN2459-6159
URN:NBNurn:nbn:hr:184:313295
Publication2013
Document URLhttps://hrcak.srce.hr/123340
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-09-23 06:38:59